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Introduction
•

The problem at hand is if treatment for
Acute Lymphoblastic Leukemia affects
neurocognitive development later in life for
pediatric cases.

•

Acute Lymphoblastic Leukemia (ALL) is
defined as a blood cancer where there are
too many lymphoblast or immature white
blood cells in the blood and bone marrow
according to the National Cancer Institute
(NCI Dictionary of Cancer Terms, 2022).

•

Neurocognitive development is defined as
how the brain develops to think and reason
according to the National Cancer Institute
(NCI Dictionary of Cancer Terms, 2022).
Neurocognition includes things such as
attention, memory, information processing,
and understanding.

•

In the United States alone nearly 3,000 children and
adolescents will be diagnosed with ALL yearly (Acute
Lymphoblastic Leukemia (ALL), 2022).

•

That shows many children are getting the
diagnosis of ALL so it is important to
understand if neurocognitive issues are
most likely to occur later in life and how one
can address these issues.

Purpose Statement
Does treatment of pediatric acute
lymphoblastic leukemia affect
neurocognitive development? If
so, does a certain treatment plan
have more effect?

Background and Significance
•
•
•
•

•

•

In the United States alone nearly 3,000 children and
adolescents will be diagnosed with ALL yearly (Acute
Lymphoblastic Leukemia (ALL), 2022).
ALL is the most common childhood cancer
representing 26% of all childhood cancers
(hfoelsing, 2018).
20-40% of those that survive ALL have
neurological deficits later in life depending on
treatment protocol (Kızılocak & Okcu, 2019).
This causes a significant problem for society because as
these children develop, they will suffer from the effects
treatments have left on them which can lead to
neurocognitive issues later.
According to St. Jude Children’s Research Hospital on
average children cancer treatment can last more than
three years and can cost 425,000 USD (Our unique
operating model, 2021).
The issue is significant to nursing practice because we
have to offer the support and guidance in how to
overcome/ease the neurocognitive effects that these
children will be faced with as the mature into adults.

(hfoelsing, 2018)

Findings

Conclusions and Nursing Implications

In research and studies surrounding
neurocognitive development of
children treated for pediatric ALL
similar findings have been observed.
Those that have received treatment for
ALL as a pediatric patient have had
neurocognitive development issues
occur as an effect of treatment (Turhan
et al., 2017). Different treatment
protocols have different effects on the
cognitive deficit that occurs in patients
later in life.
• Children diagnosed with cancer are
placed into risk groups based on how
high risk their cancer prognosis is.
Based on Ashford's study, regardless
of the risk group there is a cognitive
deficit in those treated (Ashford et al.,
2010).
• Attention is affected by treatment of
ALL in children and specifically the
areas of focus, sustained attention,
and vigilance (Koener et al., 2019).
• Children treated with just
chemotherapy do not show as much of
a neurocognitive deficit as those that
are treated with cranial radiation
therapy (CRT) as well (Krull et al.,
2013).
• Impairment for those without
CRT was 15.9%.
• Impairment for those with CRT
was 31.7%.
• Younger children at diagnosis have a
stronger neurocognitive deficit as do
females and those that have had a
relapse in cancer (Freycon et al.,
2022).
• Prophylactic intervention including
cognitive training and academic
monitoring is the best prevention
method for late term affects but does
not mean that they still will not occur
(Turhan et al., 2017).

The studies revealed that different ALL treatment
protocols have worse effects on neurocognitive
development specifically to the younger population
as they are developing more. They also showed
that there is a major attention and memory deficit
as a result of treatment since all studies focused
on these subcategories of neurocognition. As
nurses must face these issues, we can implement
referrals to neuropsychologists to provide the
necessary interventions of these late effects
(Koener et al., 2019). Further research is needed
to access what intervention the nurse must provide
aside from providing support to the patient and
family as they try to navigate the challenges
related to post treatment of pediatric cancer. I am
hopeful that this information is an eye opener to
the realness of post treatment cognitive effects.
Just because a child's cancer battle is over does
not mean their battle is over. These children have
a lifetime of cognitive issues to overcome as they
grow into adulthood.

Literature Review
•

Five articles were selected from online
databases, such as PubMed, ACS
Journals, and MDPI. Access was granted to
these online articles using my university
library.

•

The articles consisted of quantitative and
qualitative studies.

•

Key words searched included pediatric ALL,
neurocognitive development, treatments of
ALL, impacts after remission.

•

Inclusion criteria: survivor of pediatric ALL.

•

Exclusion criteria: publication date and
peer-review status.
• All articles were published
between 2010-2022 and were also
peer-reviewed.
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